Search
Menu
Home
Sources
About
Contacts
Cemiplimab
Cemiplimab
is a
monoclonal antibody
drug
for the
treatment
of
squamous cell skin cancer
,
myeloma
, and
lung cancer
.
In
Sept
2018
it was
approved
by the
US FDA
for
treating
"patients with
metastatic
cutaneous
squamous cell carcinoma
or locally advanced
CSCC
who are not candidates for
curative
surgery
or curative radiation".
Mechanism
of action
It
targets
PD-1
so it acts as a
checkpoint inhibitor
.